Ricard-Blum Sylvie
Laboratoire d'Ingénierie des Macromolécules, Institut de Biologie Structurale, 41, rue Jules Horowitz, 38027 Grenoble, France.
J Soc Biol. 2003;197(1):41-4.
The name matricryptin was proposed by Davis et al. (2000) for enzymatic fragments of extracellular matrix containing exposed matricryptic sites. The exposure of these sites occurred after structural or conformational modifications. Matricryptins derived from non fibrillar collagens (IV, VIII, XV and XVIII) and from matrix metalloproteinase-2 inhibit angiogenesis and tumor growth. Proteolysis of SPARC releases several peptides which exert opposite effects on angiogenesis. Matricryptins derived from glycosaminoglycans also participate in the control of angiogenesis.
“基质隐窝蛋白”这一名称由戴维斯等人（2000年）提出，用于指含有暴露的基质隐窝位点的细胞外基质酶解片段。这些位点在结构或构象修饰后暴露出来。源自非纤维状胶原蛋白（IV型、VIII型、XV型和XVIII型）以及基质金属蛋白酶-2的基质隐窝蛋白可抑制血管生成和肿瘤生长。富含半胱氨酸的酸性分泌蛋白（SPARC）的蛋白水解会释放出几种对血管生成产生相反作用的肽。源自糖胺聚糖的基质隐窝蛋白也参与血管生成的调控。
